Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. Methods: The REACH-B, aM...

Full description

Bibliographic Details
Main Authors: Young-Suk Lim, Henry L.Y. Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry L.A. Janssen, Calvin Q. Pan, Wan Long Chuang, Namiki Izumi, Scott Fung, Shalimar, Maurizia Brunetto, Aric Josun Hui, Ting-Tsung Chang, Seng Gee Lim, Frida Abramov, John F. Flaherty, Hongyuan Wang, Leland J. Yee, Jia-Horng Kao, Edward Gane, Jinlin Hou, Maria Buti
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:JHEP Reports
Subjects:
REACH-B
aMAP
mPAGE-B
incidence
antiviral therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923001787

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923001787

Similar Items